Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | IL6ST | P40189 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560997 | 1.00 | PPARA (0.44) | PPARAIL6STCACNA1GIDH1FAAH | |
| SCHEMBL12287709 | 1.00 | PPARA (0.44) | PPARAIL6STCACNA1GIDH1FAAH | |
| SCHEMBL19923283 | 1.00 | PPARA (0.44) | PPARAIL6STCACNA1GIDH1FAAH | |
| SCHEMBL2206996 | 0.92 | PPARA (0.47) | PPARAIL6STIDH1FAAHLTB4R | |
| SCHEMBL7406075 | 0.92 | PPARA (0.47) | PPARAIL6STIDH1FAAHLTB4R | |
| SCHEMBL3856583 | 0.89 | PPARA (0.44) | PPARAIL6STIDH1FAAHPOLB | |
| SCHEMBL5878038 | 0.89 | PPARA (0.44) | PPARAIL6STIDH1FAAHPOLB | |
| SCHEMBL21435764 | 0.89 | PPARA (0.44) | PPARAIL6STIDH1FAAHPOLB | |
| SCHEMBL21435819 | 0.89 | PPARA (0.44) | PPARAIL6STIDH1FAAHPOLB | |
| SCHEMBL3856585 | 0.89 | PPARA (0.44) | PPARAIL6STIDH1FAAHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | disclosed |
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-107266419-B | Certain amino-pyridazines, compositions thereof, and methods of use thereof | 赛特凯恩蒂克公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2563365-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2560653-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560488-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
| WO-2011133888-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133920-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | MUSK, PYGM, TNNC1 | PPARA 1296/4885IL6ST 1126/4885CACNA1G 2964/4885 |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | GRM7, GRM2, GRM1 | PPARA 1031/4885IL6ST 465/4885CACNA1G 581/4885 |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | PPARA 1679/4885IL6ST 831/4885CACNA1G 3150/4885 |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | PPARA 1296/4885IL6ST 1126/4885CACNA1G 2964/4885 |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | PPARA 3281/4885IL6ST 2395/4885CACNA1G 2045/4885 |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | PPARA 3281/4885IL6ST 2395/4885CACNA1G 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.